Inouye Eye Hospital, Chiyoda-ku, Tokyo, Japan.
J Ocul Pharmacol Ther. 2011 Dec;27(6):581-7. doi: 10.1089/jop.2011.0057. Epub 2011 Oct 19.
Latanoprost 0.005%/timolol maleate 0.5% combination eye drops are now available in Japan. The aim of the present study was to investigate the prospective intraocular pressure (IOP) reduction effects and adherence with the combination eye drops in Japanese patients.
The subjects were 162 patients (162 eyes) with glaucoma or ocular hypertension concomitantly using latanoprost 0.005% and timolol maleate 0.5% eye drops. Concomitant use of the 2 eye drops was stopped, and patients were switched to the latanoprost 0.005%/timolol maleate 0.5% combination eye drops without any washout period. IOP was measured before the switch, and at 1 and 3 months after the switch, and then compared. A questionnaire survey on adherence was also conducted 1 month after the switch.
IOP was the same before and after the switch: 15.2±3.3 mmHg before the switch, 14.9±3.0 mmHg 1 month after the switch, and 15.1±3.2 mmHg 3 months after the switch. According to the questionnaire survey, the frequency of forgetting to administer eye drops decreased with the switch, but 45.1% of the patients experienced irritation. About 82.1% replied that they preferred the latanoprost 0.005%/timolol maleate 0.5% combination eye drops. By the third month after the switch, 13 patients (8.0%) had discontinued the eye drops due to side effects or insufficient IOP reduction.
The switch from the concomitant use of latanoprost 0.005% and timolol maleate 0.5% eye drops to latanoprost 0.005%/timolol maleate 0.5% combination eye drops improved adherence and helped maintain IOP.
拉坦前列素 0.005%/马来酸噻吗洛尔 0.5%滴眼液目前在日本上市。本研究旨在观察拉坦前列素 0.005%/马来酸噻吗洛尔 0.5%滴眼液对日本患者的降眼压效果及用药依从性。
本研究共纳入 162 例（162 眼）青光眼或高眼压患者，这些患者同时使用拉坦前列素 0.005%和马来酸噻吗洛尔 0.5%滴眼液。停止两种滴眼液的同时使用，转换为拉坦前列素 0.005%/马来酸噻吗洛尔 0.5%滴眼液，无需冲洗期。在转换前、转换后 1 个月和 3 个月分别测量眼压，并进行比较。转换后 1 个月还进行了用药依从性问卷调查。
转换前后眼压无明显变化：转换前眼压为 15.2±3.3mmHg，转换后 1 个月为 14.9±3.0mmHg，转换后 3 个月为 15.1±3.2mmHg。问卷调查显示，转换后滴眼次数减少，漏用情况减少，但 45.1%的患者出现眼部刺激症状。约 82.1%的患者表示更喜欢拉坦前列素 0.005%/马来酸噻吗洛尔 0.5%滴眼液。转换后 3 个月，因不良反应或眼压降低不足而停药的患者有 13 例（8.0%）。
由拉坦前列素 0.005%和马来酸噻吗洛尔 0.5%滴眼液联合使用转换为拉坦前列素 0.005%/马来酸噻吗洛尔 0.5%滴眼液，可提高患者的用药依从性，有助于维持眼压。
